Tibet Aim Pharm., Inc. (002826) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Tibet Aim Pharm., Inc.

Why is Tibet Aim Pharm., Inc. ?

Poor long term growth as Net Sales has grown by an annual rate of 0.17% and Operating profit at 21.03% over the last 5 years

The company has declared Positive results for the last 3 consecutive quarters

ROCE(HY) Highest at 11.69%
INTEREST COVERAGE RATIO(Q) The company hardly has any interest cost
RAW MATERIAL COST(Y) Fallen by -5.05% (YoY)

With ROE of 11.20%, it has a expensive valuation with a 2.44 Price to Book Value

Over the past year, while the stock has generated a return of -33.44%, its profits have risen by 144.8% ; the PEG ratio of the company is 0.2
At the current price, the company has a high dividend yield of 1.6

Underperformed the market in the last 1 year

Even though the market (China Shanghai Composite) has generated returns of 23.91% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -33.44% returns

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Tibet Aim Pharm., Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Tibet Aim Pharm., Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Tibet Aim Pharm., Inc.

-27.67%

2.07

46.73%

China Shanghai Composite

21.43%

1.73

13.79%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

0.17%

EBIT Growth (5y)

21.03%

EBIT to Interest (avg)

24.78

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.60

Sales to Capital Employed (avg)

0.82

Tax Ratio

21.41%

Dividend Payout Ratio

30.00%

Pledged Shares

Institutional Holding

ROCE (avg)

6.70%

ROE (avg)

6.15%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

2.44

EV to EBIT

19.10

EV to EBITDA

16.05

EV to Capital Employed

6.92

EV to Sales

2.11

PEG Ratio

0.15

Dividend Yield

1.61%

ROCE (Latest)

36.21%

ROE (Latest)

11.20%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

No Signal

Bearish

Bollinger Bands

Mildly Bearish

Mildly Bullish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

15What is working for the Company

ROCE(HY)

Highest at 11.69%

INTEREST COVERAGE RATIO(Q)

The company hardly has any interest cost

RAW MATERIAL COST(Y)

Fallen by -5.05% (YoY

NET PROFIT(9M)

Higher at CNY 74.67 MM

CASH AND EQV(HY)

Highest at CNY 1,171.22 MM

DEBT-EQUITY RATIO (HY)

Lowest at -75.6 %

DEBTORS TURNOVER RATIO(HY)

Highest at 19.32 times

NET SALES(Q)

Highest at CNY 182.58 MM

-4What is not working for the Company

INTEREST(9M)

At CNY 0.5 MM has Grown at 6.67%

INVENTORY TURNOVER RATIO(HY)

Lowest at 2.69 times

Here's what is working for Tibet Aim Pharm., Inc.

Net Profit

At CNY 74.67 MM has Grown at 197.78%

Year on Year (YoY)

MOJO Watch

Net Profit trend is very positive

Net Profit (CNY MM)

Net Sales

Highest at CNY 182.58 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (CNY MM)

Net Sales

At CNY 182.58 MM has Grown at 22.92%

Year on Year (YoY)

MOJO Watch

Near term sales trend is positive

Net Sales (CNY MM)

Cash and Eqv

Highest at CNY 1,171.22 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Debt-Equity Ratio

Lowest at -75.6 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Debtors Turnover Ratio

Highest at 19.32 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Net Profit

Higher at CNY 74.67 MM

than preceding 12 month period ended Mar 2026

MOJO Watch

In the nine month period the company has already crossed sales of the previous twelve months

Net Profit (CNY MM)

Raw Material Cost

Fallen by -5.05% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Tibet Aim Pharm., Inc.

Interest

At CNY 0.5 MM has Grown at 6.67%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Inventory Turnover Ratio

Lowest at 2.69 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio